Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
Market
Immuno-oncology
Location
La Jolla,
California,
USA
Coinvestors
avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Myeloma Investment Fund, Osage University Partners, Prostate Cancer Foundation, Vivo Capital